Comparative analysis revealed that compared with pre-chemotherapy levels, there was an increase in the numbers of CD3 + and CD3 + CD4 + cells, the CD4 +/CD8 + ratio, and the number of NK cells in prostate cancer patients. This evidence concerns the gene CD8A and prostate carcinoma.